CLO & SecretaryCIK 0001950232
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 0 | Reardon AndrewCLO & Secretary |  LGNDLIGAND PHARMACEUTICALS INCOption exercise · 10b5-1 plan | M | — 5,000 sh | Nov 4, 2026 traded Nov 2, 2026 | |
Reardon AndrewCLO & Secretary |
| LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan |
| M |
| $261K 5,000 sh |
| Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $87K 283 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $218K 708 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $162K 522 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $152K 490 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $162K 520 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $198K 634 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $126K 403 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 0 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $25K 80 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $89K 280 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $140K 440 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $102K 320 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $64K 200 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 0 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $39K 120 sh | Nov 4, 2026 traded Nov 2, 2026 |
| 4 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $252K 833 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 0 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 340 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $72K 235 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $124K 404 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 4 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $467K 1,535 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 8 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $600K 1,976 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 0 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $18K 340 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 0 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $5,232 17 sh | Oct 6, 2026 traded Oct 2, 2026 |
| 12 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $116K 400 sh | Sep 8, 2026 traded Sep 3, 2026 |
| 12 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $111K 385 sh | Sep 8, 2026 traded Sep 3, 2026 |
| 19 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $606K 2,115 sh | Sep 8, 2026 traded Sep 3, 2026 |
| 15 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $513K 1,800 sh | Sep 8, 2026 traded Sep 3, 2026 |
| 12 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $85K 300 sh | Sep 8, 2026 traded Sep 3, 2026 |
| 2 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 5,000 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 1 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Other acquisition or disposition · 10b5-1 plan | J | $21K 132 sh | Jul 6, 2026 traded Jun 30, 2026 |
| 8 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $261K 5,000 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 7 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $122K 396 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 4 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $32K 104 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 10 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $349K 1,119 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 10 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $338K 1,081 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 7 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $219K 700 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 4 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $31K 100 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 10 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $284K 900 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 7 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $190K 600 sh | Jul 6, 2026 traded Jul 1, 2026 |
| 16 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $152K 677 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 19 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $324K 1,432 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 16 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $91K 400 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 19 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $279K 1,216 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 0 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 5,000 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 13 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $46K 200 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 16 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $133K 584 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 2 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $261K 5,000 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 16 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $110K 491 sh | Jun 2, 2026 traded Jun 1, 2026 |
| 6 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $181K 780 sh | May 4, 2026 traded May 1, 2026 |
| 6 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $187K 800 sh | May 4, 2026 traded May 1, 2026 |
| 0 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | — 5,000 sh | May 4, 2026 traded May 1, 2026 |
| 2 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $261K 5,000 sh | May 4, 2026 traded May 1, 2026 |
| 6 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $136K 600 sh | May 4, 2026 traded May 1, 2026 |
| 6 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $213K 932 sh | May 4, 2026 traded May 1, 2026 |
| 3 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $23K 98 sh | May 4, 2026 traded May 1, 2026 |
| 6 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $85K 370 sh | May 4, 2026 traded May 1, 2026 |
| 9 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $331K 1,420 sh | May 4, 2026 traded May 1, 2026 |
| 23 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Grant or award | A | — 4,513 sh | Mar 27, 2026 traded Mar 2, 2026 |
| 19 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Grant or award | A | — 21.5K sh | Mar 27, 2026 traded Mar 2, 2026 |
| 15 | Reardon AndrewCLO & Secretary | LGNDLIGAND PHARMACEUTICALS INC Open-market sale · 10b5-1 plan | SELL | $19K 93 sh | Mar 6, 2026 traded Mar 4, 2026 |